General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Novartis International BioCamp 2012

Novartis International BioCamp highlights global R&D reach to meet patient needs in emerging markets

Today’s best young talent will soon be changing the world. The Novartis International Biotechnology Leadership Camp (BioCamp) offers university students the opportunity to apply their bright minds to the trends and challenges of the life sciences industry – and to think like entrepreneurs.

Sixty graduate students, selected from leading universities in 21 countries and territories, gathered from August 27 to 29, 2012, at the Novartis headquarters in Basel, Switzerland, for the annual International BioCamp.

“BioCamp is such an exciting opportunity. Dozens of people from all over the world with different backgrounds and cultures are here to learn and discuss the future of healthcare. It’s really amazing.”

– 2012 International BioCamp participant.

Emerging growth markets

This year, BioCamp is emphasizing increased access to healthcare and the importance of research and development (R&D) in emerging markets and how the company’s innovative approach is expanding its global reach in clinical development. Novartis continues its commitment to sustained investment in R&D to develop targeted therapies that could change the practice of medicine and deliver the highest benefit for patients. This is particularly evident in the approach Novartis takes in emerging markets, which represent an important and growing sector for innovation and clinical development. For example, in Hyderabad, India, Novartis has built a world-class clinical development center with more than 1,000 local associates.

“Accelerating growth in emerging markets is complementing our strength in Europe and North America, and is key to delivering our long term vision for the company. Close working relationships with local healthcare providers improves patient care and access in developed and emerging markets,” said Joseph Jimenez, CEO of Novartis. “We hope to see these BioCamp students lead us into a future where patients all over the world receive optimal care.”

Annual event brings top students to Novartis Campus

Since launching BioCamp in 2004, Novartis has introduced more than 500 top graduate students to the life sciences industry and entrepreneurship. This year the students heard from Rolf M. Zinkernagel, M.D., a Nobel Prize Laureate and member of the Novartis AG Board of Directors, and Prof. Susan Gasser, Director of Friedrich Miescher Institute for Biomedical Research, among others. BioCamp students also interact with Novartis scientists and executives who lead the company’s approach to drug development, and learn about breakthrough new medicines to address patients’ unmet medical needs.

The program is designed to help students understand trends and challenges in the biotechnology and life science sectors as well as gain first-hand experience about starting and running a biotech company. BioCamp has helped bridge into local communities and build connections to aid future collaborations in research and clinical development.